CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 152 enrolled
Drug / intervention
IDP-118 Lotion +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02785159
NCT02785159Phase 2Completed

A Phase 2, Multicenter, Double Blinded, Randomized, Vehicle Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion With Tazorac (Tazarotene) Cream, 0.05% in the Treatment of Plaque Psoriasis

Bausch Health Americas, Inc.·interventional·Posted May 27, 2016·Updated Aug 20, 2020

In Brief

A Phase 2 clinical trial evaluating IDP-118 Lotion, Tazorac Cream, and 2 other interventions for Psoriasis. Completed, enrolled 152 participants across 14 sites.

Detailed Summary

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 27, 2016
Enrollment StartFeb 1, 2016
Primary CompletionNov 20, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.1 years ago

Interventions

IDP-118 Lotiondrug

Lotion

Tazorac Creamdrug

Cream

IDP-118 Vehicle Lotiondrug

Lotion

IDP-118 Vehicle Creamdrug

Cream